FGF21 and metabolic dysfunction-associated steatotic liver disease: Most importantly, however, clinical and mouse studies have reported increased plasma FGF21 concentration in patients and animal models of MASLD, and thus FGF21 has been proposed as a marker of liver steatosis (57–60).